List of Excipients in Branded Drug GLOPERBA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Scilex Pharmaceuticals Inc	GLOPERBA	colchicine	69557-222	ANHYDROUS CITRIC ACID
Scilex Pharmaceuticals Inc	GLOPERBA	colchicine	69557-222	BENZYL ALCOHOL
Scilex Pharmaceuticals Inc	GLOPERBA	colchicine	69557-222	CHERRY

GLOPERBA Excipient Strategy and Commercial Opportunities in Colchicine Oral Solution

Last updated: September 24, 2026

GLOPERBA is a ready-to-use colchicine oral solution developed by Avion Pharmaceuticals. Its commercial differentiation comes from dosage-form convenience rather than a new colchicine molecule. The formulation uses an aqueous, sweetened, flavored liquid with buffering and preservative excipients to support oral dosing, palatability, microbial control, and product stability.[1]

The strongest commercial opportunities are dose flexibility, use by patients who cannot swallow tablets or capsules, and substitution for extemporaneously compounded colchicine liquids. The principal risks are colchicine’s narrow therapeutic index, medication-error exposure, preservative and flavor tolerance, and the potential for generic manufacturers to replicate the dosage form after regulatory and intellectual-property barriers decline.

What is GLOPERBA and what excipients does it contain?

GLOPERBA is an oral solution containing 0.6 mg of colchicine per 5 mL. The labeled indication is prophylaxis of gout flares in adults. The product is administered orally and is supplied as a liquid rather than a tablet or capsule.[1]

The FDA labeling identifies the following inactive ingredients:

Excipient	Formulation function
Glycerin	Co-solvent, humectant, mouthfeel modifier
Sodium benzoate	Antimicrobial preservative
Sucralose	High-intensity sweetener
Natural flavor	Taste masking
Citric acid, anhydrous	Acidulant and pH adjustment
Sodium citrate dihydrate	Buffering agent
Purified water	Primary vehicle

The formulation is designed to solve practical problems associated with solid oral colchicine, including swallowing difficulty and the need for precise liquid measurement. The 0.6 mg per 5 mL concentration also aligns with a familiar colchicine dose, reducing conversion complexity for prescribers and pharmacists.[1]

How does the GLOPERBA excipient system support commercial differentiation?

The excipient system has four commercial functions.

1. It creates a ready-to-administer dosage form

GLOPERBA eliminates the need for pharmacy compounding from colchicine tablets or bulk material. A commercially manufactured oral solution provides standardized concentration, labeled storage instructions, quality testing, and packaged dosing instructions.

This distinction is commercially relevant in patients who require liquid administration but do not have access to a compounding pharmacy. It also reduces variability associated with compounded preparations.

2. It supports palatability

Colchicine has a bitter taste. GLOPERBA uses sucralose and natural flavor to improve acceptability. Glycerin contributes viscosity and mouthfeel, which can reduce the perception of a thin, aqueous product.

Taste performance is important because colchicine prophylaxis may be taken repeatedly over extended periods. A liquid that is technically dose-accurate but poorly tolerated can lose adherence advantages over tablets.

3. It provides microbial protection

Sodium benzoate is used as a preservative in the aqueous formulation. The citrate system supports acidic pH conditions that can improve preservative performance and help maintain product stability.

The commercial tradeoff is that preservative systems require control of pH, preservative concentration, container compatibility, and microbial limits throughout shelf life and in-use handling. Preservative performance is a regulatory and manufacturing barrier, but it is not necessarily a durable exclusivity barrier by itself.

4. It permits dose measurement without tablet manipulation

A liquid allows the prescriber to specify a measured volume rather than requiring tablet splitting, crushing, or dissolution. That may be valuable for patients with dysphagia, altered anatomy, or difficulty handling solid dosage forms.

The advantage depends on the supplied dosing device and the clarity of the label. Because colchicine toxicity can be severe, the product must minimize confusion between milligrams and milliliters.

What patient populations create the largest commercial opportunity?

The primary target is the adult gout market, especially patients who need chronic flare prophylaxis and cannot reliably use solid oral dosage forms.

Patient segment	Commercial rationale	Key limitation
Adults with dysphagia	Liquid is easier to swallow	Requires accurate measuring device
Older adults with polypharmacy	May simplify administration	High risk of medication errors and renal impairment
Patients using feeding tubes	Liquid may be operationally easier	Tube compatibility and flushing instructions matter
Patients requiring nonstandard measured volumes	Supports dose-volume adjustment	Labeling must prevent dosing confusion
Patients without compounding access	Ready-to-use product avoids pharmacy preparation	Retail availability and reimbursement remain important
Caregivers administering medication	Liquid can support supervised dosing	Spillage and measurement errors can reduce accuracy

The pediatric opportunity requires caution. A liquid dosage form is technically attractive for children, but commercial expansion into pediatric indications would depend on FDA-approved labeling, pediatric dosing data, pharmacokinetic evidence, safety findings, and age-appropriate administration instructions. The existence of a liquid formulation does not itself establish pediatric approval.

What formulation patents protect GLOPERBA?

GLOPERBA’s most defensible intellectual-property position is likely to reside in formulation, manufacturing, packaging, and dosing-system claims rather than in colchicine composition-of-matter claims. Colchicine is an established active ingredient with longstanding prior use.

Potential claim categories include:

1. A stable aqueous colchicine solution.
2. Specific colchicine concentration ranges.
3. Buffer and preservative combinations.
4. pH-controlled formulations.
5. Taste-masked liquid compositions.
6. Container-closure systems that preserve potency and microbial quality.
7. Dosing devices or dose-volume instructions.
8. Manufacturing processes for achieving content uniformity and stability.

The commercial value of such claims depends on their scope and validity. A narrow claim directed to one excipient combination may be designed around by substituting another buffer, preservative, sweetener, or flavor. A broader claim covering the functional formulation space would provide stronger protection but would face greater prior-art and obviousness challenges.

No biologic component is involved. Biosimilar risk is therefore not relevant to GLOPERBA. The relevant competitive threat is an ANDA-based generic oral solution, a competing colchicine liquid, or pharmacy-compounded product.

What is the Orange Book and regulatory status of GLOPERBA?

GLOPERBA is an FDA-approved prescription drug product regulated under an NDA pathway. Its regulatory value comes from approval of the finished oral solution, including its formulation, manufacturing controls, stability data, labeling, and quality specifications.[1]

The regulatory distinction is important:

• A generic tablet or capsule would not automatically be substitutable for the liquid.
• A generic oral solution would need to demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for the reference product.
• A competing liquid could require its own NDA if it does not qualify for an ANDA pathway.
• Listed patents and regulatory exclusivities, if any, determine whether an ANDA applicant can obtain approval and launch immediately.

The FDA Orange Book is the controlling source for current patent listings and exclusivity information. Product-specific patent status should be evaluated by reference to the current GLOPERBA listing, FDA patent-listing records, and the applicable Orange Book entry.[2]

When does GLOPERBA lose exclusivity?

The practical loss-of-exclusivity date depends on several separate rights:

Exclusivity layer	Relevance to GLOPERBA
New chemical entity exclusivity	Unlikely to provide a new-chemical-entity position because colchicine is an established drug
New formulation protection	May delay or complicate competing oral solutions if valid patents are listed
Method-of-use patents	Could affect approved gout-prophylaxis use, but not necessarily all liquid products
Pediatric exclusivity	Depends on an FDA pediatric exclusivity award
Patent term	Depends on the specific patent, filing date, prosecution history, and any patent-term adjustment
Regulatory exclusivity	Depends on FDA-designated exclusivity tied to the approved application
Trade secrets	May protect process know-how but does not block independent development

A competitor may enter before all patent disputes are resolved if it certifies that listed patents are invalid, unenforceable, or not infringed. Under Hatch-Waxman, a Paragraph IV certification can trigger patent litigation and an automatic statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation outcomes.[3]

No public Paragraph IV challenge or settlement should be treated as established without a current FDA filing record, court docket, or company disclosure. A commercial diligence review should separate actual ANDA litigation from speculation based on the age of colchicine patents.

Which companies are challenging GLOPERBA?

The competitive field includes three groups:

Generic drug manufacturers

Generic companies can target colchicine tablets, capsules, or an oral solution. A tablet generic does not directly replicate GLOPERBA’s patient-use advantages, but it can exert price pressure on prescribers and payers.

An oral-solution ANDA would represent the most direct threat. Its development would likely focus on:

• Colchicine concentration matching.
• Formulation similarity.
• Taste and preservative performance.
• Stability in the commercial container.
• Dose-delivery accuracy.
• Bioequivalence and comparative quality requirements.

Compounding pharmacies

Compounded colchicine liquids can compete on flexibility, particularly when a patient needs a concentration or flavor not supplied by GLOPERBA. Their weaknesses include variability in availability, reimbursement, quality systems, beyond-use dating, and pharmacy access.

GLOPERBA’s commercial advantage is strongest where clinicians and payers value a validated, manufactured product over individualized compounding.

Alternative gout therapies

Colchicine competes with NSAIDs, corticosteroids, urate-lowering therapy, and other anti-inflammatory approaches. GLOPERBA does not compete only against other colchicine products. Its market access depends on whether the liquid formulation solves a recognized administration problem that justifies a branded price.

How strong is the GLOPERBA patent estate?

The estate should be assessed as moderate if protection depends mainly on formulation and manufacturing claims.

Strengths

• Colchicine oral solution can present meaningful formulation and stability challenges.
• Taste masking, preservative efficacy, and dose uniformity create technical development requirements.
• A validated commercial product can be difficult to copy exactly without analytical and stability work.
• Container and dosing-device integration may create additional claim opportunities.

Weaknesses

• The active ingredient is old and widely known.
• Many individual excipients are conventional pharmaceutical ingredients.
• Generic developers can pursue alternative excipient systems.
• Formulation claims may face obviousness challenges when they combine known colchicine, aqueous vehicles, sweeteners, buffers, and preservatives.
• Trade secrets do not prevent independent reverse engineering of the finished product.

The strongest protection would generally come from claims that connect composition, stability, manufacturing process, and container closure in a way that is difficult to design around. A claim limited to a conventional excipient combination would provide less durable protection.

What manufacturing and IP barriers affect generic launch?

The principal technical barriers are:

1. Maintaining colchicine uniformity at low concentration.
2. Controlling degradation across shelf life.
3. Preserving palatability after storage.
4. Demonstrating preservative effectiveness.
5. Preventing adsorption or interaction with the bottle and dosing device.
6. Controlling microbial quality in a multidose aqueous product.
7. Producing a dose-measuring system that minimizes milligram-to-milliliter errors.

Colchicine’s narrow therapeutic index increases the commercial importance of content uniformity and dosing accuracy. A generic manufacturer may be able to reproduce the active concentration but still face development work involving flavor, viscosity, pH, preservative content, container compatibility, and in-use stability.

What licensing and business-development opportunities exist?

Potential opportunities include:

• Licensing the formulation platform to international partners.
• Regional commercialization agreements for markets where liquid colchicine is not widely available.
• Co-development of pediatric or feeding-tube administration programs, subject to regulatory support.
• Bundling the product with adherence services or specialty-pharmacy distribution.
• Licensing dosing-device technology.
• Supplying the formulation as a private-label or authorized-generic product.
• Developing alternative concentrations for specific clinical or administration needs.

The most valuable deal structure would preserve differentiation through formulation know-how, manufacturing controls, and market access rather than relying only on the colchicine molecule.

What revenue exposure does GLOPERBA face?

Revenue exposure is driven by price premium, payer coverage, prescription volume, and the percentage of patients who need a liquid. The product is unlikely to displace the entire colchicine market because tablets are familiar, inexpensive, and widely available.

The addressable commercial segment is narrower:

• Patients unable to swallow solid dosage forms.
• Patients requiring liquid administration through supervised care.
• Patients for whom compounding is unavailable or inconvenient.
• Patients whose prescribers prioritize a standardized liquid product.
• Payers willing to reimburse a branded solution over generic tablets.

The largest downside event would be approval of a substitutable generic oral solution. The impact would depend on whether the generic matches the commercial package, dosing device, flavor profile, and distribution footprint.

How does GLOPERBA compare with generic colchicine tablets?

Attribute	GLOPERBA oral solution	Generic colchicine tablet
Administration	Measured liquid	Solid oral dose
Dose flexibility	Higher	Usually fixed strength
Swallowing burden	Lower	Higher for dysphagia patients
Manufacturing complexity	Higher	Mature and standardized
Price pressure	Greater branded premium potential	Strong generic competition
Taste considerations	Material	Limited
Measurement risk	Volume-measurement risk	Tablet-selection risk
Compounding substitution	May replace compounded liquids	Does not directly replace liquid use
Patent differentiation	Formulation and device	Usually limited by older product status

Key Takeaways

• GLOPERBA’s commercial differentiation is the ready-to-use colchicine oral solution, not a new active ingredient.
• Glycerin, sucralose, natural flavor, sodium benzoate, citric acid, sodium citrate, and purified water support vehicle performance, palatability, preservation, and pH control.
• The strongest target segments are adults with dysphagia, patients requiring supervised liquid administration, and patients lacking convenient access to compounding pharmacies.
• The primary competitive threat is a generic colchicine oral solution, followed by compounded preparations and low-cost colchicine tablets.
• Formulation, manufacturing, container-closure, and dosing-device claims are more commercially relevant than colchicine composition-of-matter claims.
• Biosimilar risk does not apply because GLOPERBA is a small-molecule drug.
• Paragraph IV risk depends on current Orange Book patent listings and actual ANDA filings.
• The product’s technical barriers are real but potentially design-aroundable through alternative excipients and container systems.
• Revenue durability depends on liquid-specific patient demand, payer coverage, and the timing of generic oral-solution entry.

FAQs About GLOPERBA Excipient Strategy and Commercial Opportunities

Is GLOPERBA sugar-free?

GLOPERBA uses sucralose as its labeled sweetener. The FDA labeling identifies sucralose rather than sucrose as an inactive ingredient.[1]

Can GLOPERBA replace compounded colchicine liquid?

It can reduce the need for compounding when the labeled concentration and administration instructions meet the patient’s requirements. A compounded product may still be used when a different concentration, flavor, or formulation is required.

Why does GLOPERBA contain sodium benzoate?

Sodium benzoate functions as an antimicrobial preservative in the aqueous oral solution. Its performance depends on the formulation’s pH, concentration, container, and storage conditions.

Is GLOPERBA appropriate for pediatric patients?

A liquid dosage form may be easier for children to administer, but pediatric use depends on the FDA-approved indication, age range, dosing instructions, and supporting clinical data. The existence of an oral solution does not independently establish pediatric approval.

What is the main patent risk for a GLOPERBA competitor?

The principal risk is infringement of valid formulation, manufacturing, container-closure, or method-of-use patents listed for the product. A competitor would also face FDA requirements for an equivalent oral solution and potential Paragraph IV litigation under the Hatch-Waxman framework.

References

1. U.S. Food and Drug Administration. (n.d.). GLOPERBA (colchicine) oral solution prescribing information. Avion Pharmaceuticals.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity: Questions and answers. FDA.